Dermatofibrosarcoma Protuberans of Vulva

Dermatofibrosarcoma Protuberans of Vulva

Article
Sexual Health
Skin Care
+3
Contributed byLester Fahrner, MD+1 moreJul 21, 2022

What are the other Names for this Condition? (Also known as/Synonyms)

  • DFSP of Vulva
  • Vulvar Dermatofibrosarcoma Protuberans
  • Vulvar DFSP

What is Dermatofibrosarcoma Protuberans of Vulva? (Definition/Background Information)

  • Dermatofibrosarcoma Protuberans (DFSP) of Vulva is a very rare intermediate-grade malignant tumor of the subcutaneous tissue of skin. It is typically seen in middle-aged women
  • Generally, Dermatofibrosarcoma Protuberans of Vulva grow slowly and are present for years before they are diagnosed. They are usually painless when they are small, although large tumors can cause pain and discomfort due to pressure on the adjoining tissues and structures
  • Treatment for Dermatofibrosarcoma Protuberans of Vulva is mainly through surgery (Mohs micrographic surgery is normally recommended) and other supplementary treatment measures
  • The prognosis of Vulva Dermatofibrosarcoma Protuberans depends on the cancer stage and overall health of the individual. In general, the prognosis of the tumor is good

Who gets Dermatofibrosarcoma Protuberans of Vulva? (Age and Sex Distribution)

  • Dermatofibrosarcoma Protuberans of Vulva is commonly found in middle-aged and older adult women. A wide age range of 23-85 years has been observed
  • Individuals of all racial and ethnic background can be affected. Worldwide, no geographical localization of DFSP has been reported
  • The tumor is very rare. Fewer than 50 cases have been currently reported in the medical literature

What are the Risk Factors for Dermatofibrosarcoma Protuberans of Vulva? (Predisposing Factors)

Currently, no definitive risk factors have been reported for the development of Dermatofibrosarcoma Protuberans (DFSP) of Vulva. However, in general, DFSP has been linked to the following factors:

  • Site of trauma
  • Region of extensive burns
  • Surgical incision sites
  • Vaccinations sites (BCG vaccination)
  • Arsenic poisoning

The above mentioned risk factors are considered to be associations. Further studies to understand the risk factors are currently being undertaken.

It is important to note that having a risk factor does not mean that one will get the condition. A risk factor increases ones chances of getting a condition compared to an individual without the risk factors. Some risk factors are more important than others.

Also, not having a risk factor does not mean that an individual will not get the condition. It is always important to discuss the effect of risk factors with your healthcare provider.

What are the Causes of Dermatofibrosarcoma Protuberans of Vulva? (Etiology)

  • The exact cause of development of Dermatofibroma Protuberans of Vulva is presently unknown
  • Occasionally, certain genetic mutations have been reported; but these are still being investigated

What are the Signs and Symptoms of Dermatofibrosarcoma Protuberans of Vulva?

The clinical signs and symptoms of Dermatofibroma Protuberans of Vulva may include:

  • The presence of a nodular, painless mass, underneath the skin that is usually slow-growing
  • The skin over the mass is usually normal to reddish-brown; no ulceration of the overlying skin is noted
  • As the tumors grow and develop, the skin over the tumor may ulcerate with infection possible
  • The size of the tumor may range from 1-15 cm (average size is around 3-4 cm)
  • Most of the tumors are located on the labium major (right or left side), while some are seen on the mons pubis
  • Some lesions may present with pain and discomfort
  • Pain during sex
  • Pain in the pelvic or abdominal region
  • Vaginal bleeding, vaginal discharge
  • Urinary tract associated signs and symptoms such as frequent urination, painful urination, blood in urine (hematuria), etc.

How is Dermatofibrosarcoma Protuberans of Vulva Diagnosed?

A diagnosis of Dermatofibrosarcoma Protuberans (DFSP) of Vulva may involve the following:

  • Preliminary examination composed of:
    • Complete physical examination including pelvic exam
    • Evaluation of medical (and family) history
  • Initial diagnosis that is made by:
    • Transvaginal ultrasound of the uterus can provide an image of the vagina and surrounding pelvic organs
    • MRI scans can be used to observe if a vulvar tumor has the characteristics of cancer, along with visualizing the cancer spread (if it has spread to other areas)
    • Plain radiographs of the chest can provide evidence if the tumor has spread to the lungs
    • CT scans are rarely used in diagnosing vulvar cancer, but can be used to determine if metastasis has occurred
  • Colposcopy:
    • The cervix (including the vagina and vulva) is examined with an instrument, called a colposcope. This helps the physician get a magnified view of the region
    • In order for this procedure to be performed, the individual has to lie on a table, as for a pelvic exam. An instrument, called the speculum, is placed in the vagina to keep the opening apart, in order to help the physician, visualize the cervix. The colposcope is then used to get a magnified view of the inside
  • A tissue biopsy of the tumor mass is necessary to determine if the tumor present is a DFSP or a different benign soft tissue mass or a sarcoma. In the tissue biopsy procedure, the physician removes a sample of the tissue and sends it to the laboratory for a histopathological examination. The pathologist examines the biopsy under a microscope and arrives at a definitive diagnosis after a thorough evaluation of the clinical and microscopic findings, as well as by correlating the results of special studies on the tissues (if required)
  • The pathologist may have to distinguish this tumor from other similar tumor types (such as dermatofibroma). Differential diagnosis, to eliminate other tumor types are often considered before arriving at a definitive diagnosis

Many clinical conditions may have similar signs and symptoms. Your healthcare provider may perform additional tests to rule out other clinical conditions to arrive at a definitive diagnosis.

What are the possible Complications of Dermatofibrosarcoma Protuberans of Vulva?

The following complications may be observed with Dermatofibrosarcoma Protuberans of Vulva:

  • The tumor may spread to local tissues if it is not treated promptly
  • Ulceration of large tumor masses may get secondarily infected with bacteria or fungus
  • The rarity of the condition may cause a delayed diagnosis leading to metastasis; the frequent sites of metastasis include the local lymph nodes (most common) lungs, bones, and brain
  • The tumor may also adversely impact adjoining/surrounding structures, such as the nerves and joints, leading to discomfort or a loss of feeling
  • Topical therapy for initial stage cancers can result in side effects such as severe vaginal and vulvar irritation
  • Side effects of chemotherapy (such as toxicity) and radiation
  • Sexual dysfunction can take place as a side effect of surgery, chemotherapy, or radiation therapy
  • Recurrence of the cancer following incomplete surgical removal is known to take place (20-50% recurrence rate is seen)

How is Dermatofibrosarcoma Protuberans of Vulva Treated?

Once a diagnosis of Vulvar DFSP is made, the extent to which the tumor has spread is assessed, known as staging. The staging for vulvar cancer is based upon the FIGO (International Federation of Gynecology and Obstetrics) and the AJCC (American Joint Committee on Cancer) TNM staging systems.

The TNM classification for all vulvar cancers is given below:

Tumor extent (T):

  • Tis: The cancer is not growing into the underlying tissues. This stage, also known as carcinoma in situ, is not included in the FIGO system
  • T1: The cancer is growing only in the vulva or perineum
    • T1a: The cancer has grown no more than 1 mm into underlying tissue (stroma) and is 2 cm or smaller in size (about 0.8 inches)
    • T1b: The cancer is either more than 2 cm or it has grown more than 1 mm into underlying tissue (stroma)
  • T2: The tumor can be any size. The cancer is growing into the anus or the lower third of the vagina or urethra (the tube that drains urine from the bladder). This is called stage 2/3 in the FIGO system
  • T3: The tumor can be any size. The cancer is growing into the upper urethra, bladder or rectum or into the pubic bone. This is called stage 4 in the FIGO system

Lymph node spread of cancer (N):

  • N0: No lymph node spread
  • N1: The cancer has spread to 1 or 2 lymph nodes in the groin with the following features:
    • N1a: The cancer has spread to 1 or 2 lymph nodes and the areas of cancer spread are both less than 5 mm (about 1/5th of an inch) in size
    • N1b: The cancer has spread to one lymph node and the area of cancer spread is 5 mm or greater
  • N2: The cancer has spread to groin lymph nodes with the following features:
    • N2a: The cancer has spread to 3 or more lymph nodes, but each area of spread is less than 5 mm
    • N2b: The cancer has spread to 2 or more lymph nodes with each area of spread 5 mm or greater
    • N2c: The cancer has spread to lymph nodes and has started growing through the outer covering of at least one of the lymph nodes (called extracapsular spread)
  • N3: The cancer has spread to the lymph nodes causing open sores (ulceration) or causing the lymph node to be stuck (fixed) to the tissue below it

Distant spread of cancer (M)

  • M0: No distant spread
  • M1: The cancer has spread to distant sites (includes spread to pelvic lymph nodes)

Stage grouping: Once the T, N, and M categories have been assigned, this information is combined to assign an overall stage in a process called stage grouping. The stages identify tumors that have a similar outlook and are treated in a similar way.

Stage 0 (Tis, N0, M0):

  • This is a very early cancer found on the surface of the skin of the vulva only. It is also known as carcinoma in situ and as Bowen disease
  • This stage is not included in the FIGO system

Stage I (T1, N0, M0):

  • The cancer is in the vulva or the perineum (the space between the rectum and the vagina) or both
  • The tumor has not spread to lymph nodes or distant sites
  • Stage IA (T1a, N0, M0):
    • These are stage I cancers with tumors that are 2 cm or less that have grown into the underlying tissue no deeper than 1 mm (about 1/25 inch)
  • Stage IB (T1b, N0, M0):
    • These are stage I cancers that have invaded deeper than 1 mm and/or are larger than 2 cm

Stage II (T2, N0, M0):

  • The cancer has grown outside the vulva or perineum to the anus or lower third of the vagina or urethra (T2)
  • It has not spread to lymph nodes (N0) or distant sites (M0)
  • In FIGO, this grouping is T2/T3, N0, M0, but it is still stage II

Stage III is subdivided into 3 stages that are termed as Stage IIIA, Stage IIIB, and Stage IIIC.

Stage IIIA (T1 or T2, N1a or N1b, M0):

  • Cancer is in the vulva or perineum or both (T1) and may be growing into the anus, lower vagina, or lower urethra (T2)
  • Either it has spread to a single nearby lymph node with the area of cancer spread 5 mm or greater in size (N1a);
  • OR it has spread to 1 or 2 nearby lymph nodes with both areas of cancer spread less than 5 mm in size (N1b). It has not spread to distant sites (M0)

In FIGO, this stage is also IIIA, but it is split into IIIAi and IIIAii.

  • Stage IIIAi (T1 or T2, N1a, M0):
    • The cancer is in the vulva or perineum and may be any size and growing into the anus, lower vagina, or lower urethra (T1 or T2)
    • It has spread to a single lymph node with the area of spread 5 mm or greater in size (N1a)
    • It has not spread to distant sites (M0)
  • Stage IIIAii (T1 or T2, N1b, M0):
    • The cancer is in the vulva or perineum and may be any size and growing into the anus, lower vagina, or lower urethra (T1 or T2)
    • It has spread to 1 or 2 lymph nodes with the areas of cancer spread less than 5 mm in size (N1b)
    • It has not spread to distant sites (M0)

Stage IIIB (T1 or T2, N2a or N2b, M0):

  • Cancer is in the vulva or perineum or both (T1) and may be growing into the anus, vagina, or lower urethra (T2)
  • Either, the cancer has spread to 3 or more nearby lymph nodes, with all areas of cancer spread less than 5 mm in size (N2a)
  • OR the cancer has spread to 2 or more lymph nodes with each area of spread 5 mm or greater in size (N2b)
  • The cancer has not spread to distant sites (M0)

In FIGO, this stage is also IIIB, but it is split into IIIBi and IIIBii.

  • Stage IIIBi (T1 or T2, N2a, M0):
    • The cancer is in the vulva or perineum and may be any size and growing into the anus, lower vagina, or lower urethra (T1 or T2)
    • The cancer has spread to 3 or more nearby lymph nodes, with all areas of cancer spread less than 5 mm in size (N2a)
    • It has not spread to distant sites (M0)
  • Stage IIIBii (T1 or T2, N2b, M0):
    • The cancer is in the vulva or perineum and may be any size and growing into the anus, lower vagina, or lower urethra (T1 or T2)
    • The cancer has spread to 2 or more lymph nodes with each area of spread 5 mm or greater in size (N2b)
    • It has not spread to distant sites (M0)

Stage IIIC (T1 or T2, N2c, M0):

  • Cancer is in the vulva or perineum or both (T1) and may be growing into the anus, lower vagina, or lower urethra (T2)
  • The cancer has spread to nearby lymph nodes and has started growing through the outer covering of at least one of the lymph nodes (called extracapsular spread; N2c)
  • The cancer has not spread to distant sites (M0)

In FIGO, this stage is also called IIIC.

Stage IV is subdivided into 2 stages that are termed as Stage IVA and Stage IVB.

  • Stage IVA: Either of the following -
  • T1 or T2, N3, M0:
    • Cancer is in the vulva or perineum or both (T1) and may be growing into the anus, vagina, or lower urethra (T2)
    • Cancer spread to nearby lymph nodes has caused them to be stuck (fixed) to the underlying tissue or caused open sores (ulceration) (N3)
    • It has not spread to distant sites

In FIGO, this stage is also called IVA.

OR

  • T3, any N, M0:
    • The cancer has spread beyond nearby tissues to the bladder, rectum, pelvic bone, or upper part of the urethra (T3)
    • It may or may not have spread to nearby lymph nodes (any N). It has not spread to distant sites (M0)

In FIGO, this stage is also IVA.

  • Stage IVB (any T, any N, M1):
  • Cancer has spread to distant organs or lymph nodes (M1)
  • This is the most advanced stage of cancer

In FIGO, this stage is also IVB.

(Source: “The FIGO/AJCC system for staging vulvar cancer”; information provided by the American Cancer Society, February 2016)

Vulvar cancers are treated using several methods depending on the stage of the cancer:

In situ and initial stage cancers: Stage 0 and Stage I

  • Vulvar intraepithelial neoplasia (VIN, or vulvar precancer) may be treated using topical applications, laser surgery, or local excisional surgery. VIN has no relationship to DFSP
  • A lesser-invasive procedure, called ultrasound surgical aspiration, may be used to break the tumor into smaller segments and destroy them using ultrasound vibrations
  • In some cases, a minor procedure known as skinning vulvectomy may be undertaken, which is followed through by surgical skin grafts to cover the surgery site
  • Stage I cancers are removed either through wide local excisional surgery or radical local excisional surgery. In case lymph node involvement is noted, then the local lymph nodes are also removed
  • Radiation therapy may be an option for individuals in whom surgical intervention is not possible

Higher stage cancers: Stage II to Stage IV

  • Large-sized tumors may be removed through radical vulvectomy, modified radical vulvectomy, or by performing a radical local excisional surgery. In case the lymph nodes are involved, then they are also removed
  • Radiation therapy may be an option for individuals in whom surgical intervention is not possible, or following surgery to destroy the remaining cancer cells
  • Chemotherapy may be considered before or following surgery, either independently, or in combination with radiation therapy
  • Advanced stage cancers (stage IV) are treated through a combination of radical vulvectomy, pelvic exenteration (if necessary), and radiation therapy and/or chemotherapy
  • Individuals who cannot withstand radical surgical procedures may be treated by a combination of radiation therapy and chemotherapy. They may also be recommended for clinical trials

Recurrent cancers are treated on a case-by-case basis based on their stage and site of recurrence. They are treated through radical vulvectomy and/or pelvic exenteration invasive techniques. Often, a combination of treatment measures may be used by the healthcare providers (including recommendation for clinical trials when recurrence is associated with higher stage cancers). Advanced stage tumors with metastasis may be treated on a case-by-case basis; often symptomatic treatment with radiation and/or chemotherapy is attempted.

The treatment of Dermatofibrosarcoma Protuberans of Vulva involves surgery, which is the most common treatment option considered. Mohs' Micrographic Surgery is normally recommended to remove the tumors. In Mohs Micrographic Surgery, the first excision taken is the surgeon’s best clinical estimate of the margin between normal and cancerous tissue. The entire margin of the removed specimen is examined microscopically after staining with special immunohistochemical stains that highlight the microscopic differences between normal and malignant skin. Any remaining tumor-affected tissue is removed at the next stage (which is usually the following day because of the complexity of the staining process). As many stages are performed as needed to achieve tumor-free skin and tissues of the vulva. Once that is done, surgical reconstruction is planned and performed. 

Mohs surgery is done with the patient awake, under local anesthesia. For pain or anxiety control, oral or IV sedation may be given. Between stages, the defect is bandaged, and is painless. 

A multispecialty team of surgeons will often collaborate for the management and surgery of patients with Vulvar DFSP.

Surgery:

  • Vulvectomy: It is a surgical intervention technique to remove a part or the entire vulva. It may be of the following types:
    • If only the top layer of the skin over the vulva is removed, it is known as skinning vulvectomy. This procedure also involves the use of skin grafts (taken from other body sites) to cover surgical site
    • If only a portion of the vulva is removed, which may or may not be accompanied by removal of the affected lymph nodes; then, it is known as modified radical vulvectomy
    • If the entire vulva that is affected by cancer is removed, then it is called a radical vulvectomy. In such cases, the local lymph nodes are also removed. The entire vulva may include the clitoris and the inner and outer lips of the vagina
  • Pelvic exenteration: It is an extensive surgical procedure wherein the entire vulva, the vagina, the surrounding tissues, and the pelvic lymph nodes are removed. In addition, depending on the extent of tumor spread, parts affected around the region (such as the cervix, urinary bladder, rectum, colon, etc.) may be removed. Recovery from this surgery usually takes a long period

Chemotherapy:

  • Medications are used to kill the tumor cells, which may be given as oral pills or injected into veins
  • A combination of chemotherapy medications may be used
  • Chemotherapy may be used in addition to radiation and/or surgery, to treat cancers that have spread or recurred. When chemotherapy and radiation therapy are used together, it is called concurrent chemoradiation
  • Side effects of chemotherapy may include nausea, vomiting, hair loss, loss of appetite, diarrhea, fatigue, increased risk of infection, mouth sores, and easy bruising, depending on the drugs used

Radiation therapy:

  • This procedure uses high-energy beams to kill the cancer cells
  • These beams may be delivered from outside the body (external beam radiation therapy) or the radioactive material maybe placed inside the vagina (internal radiation therapy or brachytherapy)
  • Possible side effects may include:
    • Fatigue, nausea, vomiting, and diarrhea
    • Bladder irritation, leading to inflammation (cystitis)
    • Ovaries may be affected resulting in menstrual changes, or premature menopause
    • The vulva and vagina may be affected, causing soreness, or even scar tissue formation

Once treatment is complete, it is recommended that the individual schedule regular check-ups, based on the recommendation of the specialist treating them. 

How can Dermatofibrosarcoma Protuberans of Vulva be Prevented?

  • Currently, there are no methods to prevent the onset of Dermatofibrosarcoma Protuberans of Vulva, which is an intermediate-grade tumor
  • Regular medical screening at periodic intervals with blood tests, radiological scans, and physical examinations are mandatory for those who have been diagnosed with the tumor

What is the Prognosis of Dermatofibrosarcoma Protuberans of Vulva? (Outcomes/Resolutions)

  • Dermatofibrosarcoma Protuberans of Vulva is an intermediate-grade sarcoma, which means that a complete excision of the tumor through surgery is necessitated. With complete surgical excision of the tumor, the prognosis is usually good. The survival rates range between 91-100%, although recurrences are commonly observed in routine wide-excisional surgery. A recurrence rate of as low as 1 % has been published with Mohs Micrographic Surgery
  • The prognosis for Vulvar Dermatofibrosarcoma Protuberans depends upon a set of several factors that include: 
    • The size of the tumor and the extent of its invasion: Individuals with small-sized tumors fare better than those with large-sized tumors
    • Stage of cancer: With lower-stage tumors, when the tumor is confined to site of origin, the prognosis is usually excellent with appropriate therapy. In higher-stage tumors, such as tumors with metastasis, the prognosis is poor
    • Cell growth rate of the cancer
    • Overall health of the individual: Individuals with overall excellent health have better prognosis compared with those with poor health
    • Age of the individual: Older individuals generally have poorer prognosis than younger individuals
    • Individuals with bulky disease have a poorer prognosis
    • Involvement of the regional lymph nodes, which can adversely affect the prognosis
    • Involvement of vital organs may complicate the condition
    • The surgical resectability of the tumor (meaning if the tumor can be removed completely)
    • Whether the tumor is occurring for the first time or is a recurrent tumor. Recurring tumors have worse prognosis compared to tumors that do not recur
    • Response to treatment: Tumors that respond to treatment have better prognosis compared to tumors that do not respond to treatment
    • Progression of the condition makes the outcome worse
  • An early diagnosis and prompt treatment of the tumor generally yields better outcomes than a late diagnosis and delayed treatment
  • The combination chemotherapy drugs used, may have some severe side effects (such as cardio-toxicity). This chiefly impacts the elderly adults, or those who are already affected by other medical conditions. Individuals, who tolerate chemotherapy sessions better, generally have better outcomes
  • It is important to schedule and attend follow-up appointments with the healthcare provider. Many patients with metastatic or locally advanced tumors may be referred for clinical trials for experimental treatment options

Additional and Relevant Useful Information for Dermatofibrosarcoma Protuberans of Vulva:

  • A variety of immunostains may be used to arrive at a definitive diagnosis. Dermatofibrosarcoma Protuberans is usually positive for CD34 and vimentin
  • A common tumor called dermatofibroma may resemble Dermatofibrosarcoma Protuberans. Hence, a careful examination of the tumor is necessary. Dermatofibrosarcoma Protuberans is negative for S-100, epithelial membrane antigen, smooth muscle actin, and desmin. This immunostaining pattern will help in distinguishing it from a dermatofibroma
Was this article helpful

On the Article

Krish Tangella MD, MBA picture
Approved by

Krish Tangella MD, MBA

Pathology, Medical Editorial Board, DoveMed Team
Lester Fahrner, MD picture
Reviewed by

Lester Fahrner, MD

Chief Medical Officer, DoveMed Team

0 Comments

Please log in to post a comment.

Related Articles

Test Your Knowledge

Asked by users

Related Centers

Loading

Related Specialties

Loading card

Related Physicians

Related Procedures

Related Resources

Join DoveHubs

and connect with fellow professionals

Related Directories

Who we are

At DoveMed, our utmost priority is your well-being. We are an online medical resource dedicated to providing you with accurate and up-to-date information on a wide range of medical topics. But we're more than just an information hub - we genuinely care about your health journey. That's why we offer a variety of products tailored for both healthcare consumers and professionals, because we believe in empowering everyone involved in the care process.
Our mission is to create a user-friendly healthcare technology portal that helps you make better decisions about your overall health and well-being. We understand that navigating the complexities of healthcare can be overwhelming, so we strive to be a reliable and compassionate companion on your path to wellness.
As an impartial and trusted online resource, we connect healthcare seekers, physicians, and hospitals in a marketplace that promotes a higher quality, easy-to-use healthcare experience. You can trust that our content is unbiased and impartial, as it is trusted by physicians, researchers, and university professors around the globe. Importantly, we are not influenced or owned by any pharmaceutical, medical, or media companies. At DoveMed, we are a group of passionate individuals who deeply care about improving health and wellness for people everywhere. Your well-being is at the heart of everything we do.

© 2023 DoveMed. All rights reserved. It is not the intention of DoveMed to provide specific medical advice. DoveMed urges its users to consult a qualified healthcare professional for diagnosis and answers to their personal medical questions. Always call 911 (or your local emergency number) if you have a medical emergency!